Effect of Exercise on ADMA Level in Type 2 Diabetes Mellitus
暂无分享,去创建一个
A. Altun | B. Altun | B. Taskiran | A. Demir | Ç. H. Karadağ | S. A. Vardar
[1] I. Komuro,et al. Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus. , 2009, International journal of cardiology.
[2] J. Tanus-Santos,et al. Enhanced concentrations of relevant markers of nitric oxide formation after exercise training in patients with metabolic syndrome. , 2008, Nitric oxide : biology and chemistry.
[3] S. Yamagishi,et al. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. , 2008, Current pharmaceutical design.
[4] K. Doi,et al. Impaired flow-mediated vasodilatation and insulin resistance in type 2 diabetic patients with albuminuria. , 2008, Diabetes research and clinical practice.
[5] Nezih Hekim,et al. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus. , 2007, Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology.
[6] L. Ignarro,et al. The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio. , 2007, Pharmacology & therapeutics.
[7] S. Ueno,et al. Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients. , 2007, Endocrine journal.
[8] M. Wolzt,et al. Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with Type 2 diabetes and albuminuria , 2007, Diabetic medicine : a journal of the British Diabetic Association.
[9] Nutrition Recommendations and Interventions for Diabetes , 2007, Diabetes Care.
[10] K. Kawecka-Jaszcz,et al. Nontraditional atherosclerotic risk factors and extent of coronary atherosclerosis in patients with combined impaired fasting glucose and impaired glucose tolerance. , 2007, Metabolism: clinical and experimental.
[11] S. Yamagishi,et al. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes. , 2007, Medical hypotheses.
[12] A. Auteri,et al. Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease. , 2006, Prostaglandins & other lipid mediators.
[13] S. Yasuda,et al. Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. , 2006, European heart journal.
[14] G. Breithardt,et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. , 2006, Journal of the American Society of Nephrology : JASN.
[15] M. Wolzt,et al. Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with type 1 diabetes mellitus , 2005, Wiener klinische Wochenschrift.
[16] R. Böger. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials , 2005 .
[17] A. Coats,et al. Home‐based exercise training modulates pro‐oxidant substrates in patients with chronic heart failure , 2005, European journal of heart failure.
[18] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[19] F. Schweitzer,et al. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. , 2003, Clinica chimica acta; international journal of clinical chemistry.
[20] R. Sigal,et al. Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in Type 2 diabetes mellitus , 2003, Diabetologia.
[21] T. Lehtimäki,et al. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. , 2003, Metabolism: clinical and experimental.
[22] R. Nijveldt,et al. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. , 2002, Analytical biochemistry.
[23] R. Sigal,et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta‐analysis of controlled clinical trials , 2002, JAMA.
[24] J P Cooke,et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. , 2001, The American journal of cardiology.
[25] D. Sellen,et al. Genetics of Criminal and Antisocial Behaviour. Ciba Foundation Symposium 194. Pp. 283. Edited by G. R. Bock & J. A. Goode. (Wiley, Chichester, 1996.) £50.00. , 1998, Journal of Biosocial Science.
[26] S. Moncada,et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.
[27] A. H. Ismail,et al. Nomogram by Astrand and Ryhming as a predictor of maximum oxygen intake. , 1966, Journal of applied physiology.